What treatment options would you recommend for a 54-year-old patient with chronic depression who has already tried a medication (e.g., somant) and is seeking advice?

Treatment Recommendation for Chronic Depression After Initial Treatment Failure

For a 54-year-old with chronic depression who has not responded adequately to initial antidepressant therapy, modify treatment immediately by either switching to a different second-generation antidepressant, augmenting with cognitive behavioral therapy (CBT), or adding an augmentation agent such as bupropion, aripiprazole, or quetiapine. 1, 2

Critical First Step: Assess Treatment Adequacy

Before changing treatment, verify the patient has received an adequate trial:

• 6-8 weeks at therapeutic dose is required to determine treatment failure 1
• If less than 6 weeks or subtherapeutic dosing, optimize current medication first
• Monitor for suicidal ideation, which increases during the first 1-2 months of any antidepressant treatment 1

Evidence-Based Second-Line Strategies

The evidence shows no clear superiority among switching versus augmentation strategies 2, 3, so selection depends on:

Option 1: Switch to Different Second-Generation Antidepressant

• Moderate-quality evidence shows equivalent outcomes when switching between SSRIs, SNRIs, or bupropion 2
• Choose based on side effect profile:
  • Bupropion: Lower sexual dysfunction rates 1
  • SNRIs (venlafaxine, duloxetine): Slightly more effective but higher nausea/vomiting 4
  • Avoid paroxetine in this age group due to higher adverse effects 4

Option 2: Augment with Cognitive Behavioral Therapy

• Low-quality evidence shows equivalent response/remission to medication switching 2
• Combination therapy (antidepressant + CBT) superior to either alone for chronic/severe depression (SMD 0.30-0.33) 5
• This is particularly appropriate for chronic depression with multiple prior episodes

Option 3: Augment with Second Medication

Atypical antipsychotics (strongest evidence):

• Aripiprazole or quetiapine have demonstrated efficacy 6, 7
• Monitor metabolic side effects (weight gain, glucose, lipids)

Bupropion augmentation:

• Low-quality evidence shows decreased depression severity versus buspirone 2
• Lower discontinuation rates due to adverse events 2

Other options with evidence:

• Lithium, lamotrigine, or liothyronine (T3) 6, 7
• Mirtazapine combined with SSRI/SNRI 7

Critical Pitfall: "Somant" Identification

The medication "somant" appears to be a topical analgesic containing capsaicin, lidocaine, menthol, and methyl salicylate 8. This is NOT an antidepressant. If this patient has only tried a topical pain medication:

• Start evidence-based depression treatment immediately with either:
  • Second-generation antidepressant (SSRI, SNRI, or bupropion) 1, 2
  • CBT monotherapy 2
  • Combination of both for chronic depression 2, 5

Treatment Duration Requirements

For chronic depression (≥2 episodes):

• Continue effective treatment for 4-9 months minimum after remission 1
• Consider indefinite maintenance therapy given multiple episodes 1
• Longer duration significantly reduces recurrence risk 1

Monitoring Protocol

• Assess within 1-2 weeks of any treatment change for worsening suicidality 1
• Evaluate response at 6-8 weeks - if inadequate, modify again 1
• Use structured tools (PHQ-9 or HAM-D) to quantify response 2
• Target remission, not just response - aim for >50% symptom reduction 2

Age-Specific Considerations

At 54 years old, preferred agents include:

• Citalopram, escitalopram, sertraline, mirtazapine, venlafaxine, or bupropion 4
• Avoid paroxetine and fluoxetine due to higher adverse effect rates in older adults 4
• Monitor for drug-drug interactions if multiple comorbidities present 9

The evidence strongly supports taking action rather than continuing ineffective treatment, as up to 70% of patients do not achieve remission with initial therapy 3. The choice between switching, augmenting with therapy, or augmenting with medication should be based on patient preference, treatment history, side effect tolerance, and accessibility of CBT 2, 3.